Daily - Oct 21, 2026 - Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
CHAPTERS
00:00 SOZO Biotech Daily Brief
00:35 Fenebrutinib Cuts Relapse Rate in Multiple Sclerosis
01:11 Fenebrutinib Slows Chronic Brain Lesion Progression
01:46 Genentech Highlights Pediatric Ocrevus and Enspryng
02:23 Miv-cel Shows 1-Year Mobility Gains in Stiff Person
03:00 Miv-cel Enables Immunotherapy Freedom at One Year
03:38 Oral Olorofim Meets Non-Inferiority in Aspergillosis
04:12 Olorofim Reduces Renal Injury; Resubmission Planned
04:48 FDA Approves ORLADEYO Oral Pellets for HAE
05:30 LMN-201 Biologic Cocktail Succeeds in Phase 2 C. diff
06:13 BIOX-101 Reduces Edema Growth in Brain Hemorrhage
06:56 Servier Partners with Okomera on Tumor Miniaturization
07:37 Looking ahead
08:24 SOZO Intuition
SUMMARY
SOURCES BY CHAPTER
SOZO BIOTECH DAILY BRIEF
FENEBRUTINIB CUTS RELAPSE RATE IN MULTIPLE SCLEROSIS
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026 2026-10-21:
https://www.gene.com/media/press-releases/15139/2026-10-21/genentech-presents-new-pivotal-trial-data-across-broad-neuroimmunology-portfolio-at-mstoronto2026
FENEBRUTINIB SLOWS CHRONIC BRAIN LESION PROGRESSION
GENENTECH HIGHLIGHTS PEDIATRIC OCREVUS AND ENSPRYNG
MIV-CEL SHOWS 1-YEAR MOBILITY GAINS IN STIFF PERSON
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto…:
https://www.globenewswire.com/news-release/2026/10/21/3385400/0/en/kyverna-therapeutics-presents-full-one-year-registrational-data-set-demonstrating-sustained-clinical-benefit-of-miv-cel-in-stiff-person-syndrome-at-ms-toronto.html
Quell Therapeutics Advances QEL-005 to Second Dose Cohort in CHILL Phase 1/2 Trial in Rheumatoid Arthritis and Systemic Sclerosis 2026-10-21:
https://www.biospace.com/press-releases/promising-early-safety-data-as-quell-therapeutics-advances-qel-005-a-novel-engineered-ntreg-therapy-to-second-dose-cohort-in-chill-phase-1-2-trial-in-difficult-to-treat-rheumatoid-arthritis-and-systemic-sclerosis
Arctic Therapeutics Closes Oversubscribed US$21.5 Million Financing 2026-10-21:
https://www.prnewswire.com/news-releases/arctic-therapeutics-closes-oversubscribed-us21-5-million-financing-302915211.html
MIV-CEL ENABLES IMMUNOTHERAPY FREEDOM AT ONE YEAR
ORAL OLOROFIM MEETS NON-INFERIORITY IN ASPERGILLOSIS
Shionogi and F2G Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome Followed by Standard of Care in Invasive…:
https://www.shionogi.com/global/en/news/2026/10/e20261021_3.html
OLOROFIM REDUCES RENAL INJURY; RESUBMISSION PLANNED
FDA APPROVES ORLADEYO ORAL PELLETS FOR HAE
BioCryst Announces U.S. FDA Approval of ORLADEYO 150 mg Oral Pellets for Adults and Adolescents with Hereditary Angioedema 2026-10-21:
https://www.globenewswire.com/news-release/2026/10/21/3385361/29446/en/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae.html
LMN-201 BIOLOGIC COCKTAIL SUCCEEDS IN PHASE 2 C. DIFF
Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial of LMN-201 for C. difficile Infection 2026-10-21:
https://www.prnewswire.com/news-releases/lumen-bio-reports-positive-phase-2-results-from-the-repreve-clinical-trial-lmn-201-for-c-difficile-infection-302915046.html
BIOX-101 REDUCES EDEMA GROWTH IN BRAIN HEMORRHAGE
Bioxodes BIOX-101 Phase 2a Data Show Statistically Significant Reduction in Perihematomal Edema Growth in Intracerebral Hemorrhage 2026-10-21:
https://www.bioxodes.com/newsroom/press-releases/bioxodes-biox-101-phase-2a-data-show-statistically-significant-reduction-in-perihematomal-edema-growth-in-intracerebral-hemorrhage
SERVIER PARTNERS WITH OKOMERA ON TUMOR MINIATURIZATION
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research 2026-10-21:
https://www.okomera.com/_files/ugd/631ec0_f041bdf1df614649962c581bf1a5e735.pdf
LOOKING AHEAD
Akeso Announces Summit Therapeutics and ECOG-ACRIN Enter a Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer…:
https://www.prnewswire.com/news-releases/akeso-announces-summit-therapeutics-and-ecog-acrin-cancer-research-group-enter-into-phase-iiiii-clinical-trial-collaboration-to-evaluate-ivonescimab-in-first-line-biliary-tract-cancer-302915469.html
Muna Therapeutics Announces Positive Phase 1 Results Supporting Potential of Oral Small-Molecule TREM2 Modulator MNA-001 in Alzheimer Disease 2026-10-21:
https://www.prnewswire.com/news-releases/muna-therapeutics-announces-positive-phase-1-results-supporting-potential-of-oral-small-molecule-trem2-modulator-mna-001-in-alzheimers-disease-302914619.html
Additional references omitted to fit YouTube's 5,000-character limit.